Response To: “A Somatization Comorbidity Phenotype Impacts Response to Therapy in Rheumatoid Arthritis: Post Hoc Results From the Certolizumab Pegol Phase 4 PREDICT Trial”

Arthritis Research & Therapy
doi 10.1186/s13075-019-1848-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC


Related search